About

Welcome to the Cardiometabolic Forum, an educational website developed under the auspices of the University of Glasgow and dedicated to the dissemination of the latest developments in the field of cardiometabolic diseases. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of cardiometabolic diseases, their treatments and clinical practice.

Our content is free from commercial bias and features leading experts sharing their knowledge and experience in the form of videos, podcasts, and slide deck publication summaries.

Publications

Free slide summaries for a selection of papers

The Steering Committee regularly select the most relevant and up-to-date publications for review, with slide summaries of the papers available to download.

Podcasts

Free podcasts hosted by our Steering Committee

Here you will find our Cardiometabolic Forum podcasts recorded by our Steering Committee

Latest Updates

Latest ▼
All
Lit Search

Find our February Literature Highlights here

FDA

Brenzavvy (bexagliflozin) approved by the FDA in adults with type 2 diabetes mellitus as an adjunct to diet and exercise

The South Asian Health Foundation (UK) guidelines for managing diabetes during Ramadan

Publication thumbnail: Efficacy and Safety of the SGLT2 Inhibitor Empagliflozin versus Placebo and the DPP-4 Inhibitor Linagliptin versus Placebo in Young People with Type 2 Diabetes (DINAMO): a Multicentre, Randomised, Double-blind, Parallel Group, Phase 3 Trial

Efficacy and Safety of the SGLT2 Inhibitor Empagliflozin versus Placebo and the DPP-4 Inhibitor Linagliptin versus Placebo in Young People with Type 2 Diabetes (DINAMO): a Multicentre, Randomised, Double-blind, Parallel Group, Phase 3 Trial

Steering Committee